Search results for " Hepatitis C."
showing 10 items of 174 documents
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1)…
2014
Although the addition of the HCV NS3/4A protease inhibitors boceprevir and telaprevir to pegylated interferon (peginterferon) alfa plus ribavirin has improved sustained virological response (SVR) in treatment-naive and treatment-experienced patients infected with hepatitis C virus (HCV) genotype 1, the regimens have a high pill burden and are associated with increased rates and severity of adverse events, such as anaemia and rash. The efficacy and safety of the combination of simeprevir, a one pill, once-daily, oral HCV NS3/4A protease inhibitor, plus peginterferon alfa 2a plus ribavirin were assessed in treatment-naive patients with HCV genotype 1 infection.In QUEST-1, a phase 3, randomise…
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluat…
2017
Background: Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure. Aim: To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in the advanced liver disease stage. Methods: Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively collected in consecutive patients who reached the 12-week post-treatment and retreatment evaluations from January 2015 to December 2016 in 23 of the PITER network centers. Results: Among 3,830 patients with advanced fibrosis (F3) or cirrhosis, 139 (3.6%) failed to achieve SVR. Genotype 3, bilirubin lev…
Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy
2021
Background: Occurrence of hepatitis C virus (HCV) infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. Aim: To report the use of phylogenetic analysis in the clinical risk management of an HCV outbreak among 128 thalassaemia outpatients followed at a thalassaemia centre of an Italian hospital. Methods: Epidemiological investigation and root-cause analysis were performed. All patients with acute hepatitis and known chronic infection were tested for HCV RNA, HCV genotyping, and NS3, NS5A, and NS5B HCV genomic region sequencing. To identify transmission clusters, phylogenetic trees were built for each…
Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women
2014
AIM: To investigate the safety/efficacy of Boceprevirbased triple therapy in hepatitis C virus (HCV)-G1 menopausal women who were historic relapsers, partial-responders and null-responders. METHODS: In this single-assignment, unblinded study, we treated fifty-six menopausal women with HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure (7% null, 41% non-responder, and 52% relapser) with 4 wk lead-in with PEG-IFNα2b/RBV followed by PEGIFNα2b/RBV+Boceprevir for 32 wk, with an additional 12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNA-positive by week 8. In previous null-responders, 44 wk of triple therapy was used. The primary objective of retreatment was to verify whether a sustained virolo…
Resistencia a nuevos antivirales de acción directa en aislados clínicos del virus de la hepatitis C
2014
La infección crónica provocada por el virus de la hepatitis C (VHC) sigue siendo un problema de salud pública a nivel mundial y en España, ocasionando unas 10.000 muertes al año. Se estima que el 3% de la población mundial (200 millones de personas en el mundo y unas 900.000 en España) se encuentran infectadas por este virus. En España, y en el resto de países Occidentales, además de ser la principal causa de hepatitis crónica, cirrosis y carcinoma hepatocelular, la infección por VHC es la indicación más frecuente de trasplante hepático. El tratamiento convencional basado sólo en interferón pegilado más ribavirina (peg-IFN-α/RBV), provoca numerosos efectos secundarios, es de larga duración …
Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling study
2017
WOS: 000426979400014
Virus de la hepatitis C en usuarios de drogas por via parenteral
2003
El virus de la hepatitis C (VHC) tiene actualmente una gran importancia, por su preva¬lencia 1,5% en la población en general, 82 a 92% en Usuarios de drogas vía parenteral, siendo estos el grupo que tiene mayor prevalencia del VHC, por presentar mayor con¬tagio por vía sanguínea incluso que el VIH, siendo generalmente asintomático hasta la aparición de cirrosis hepática descompensada; produciendo esta en un 2,6% a los 10 años en los pacientes monoinfectados con el virus de la hepatitis C y un 14,9% en los coinfectados con el VIH, la progresión es más rápida en los coinfectados con linfocitos CD4>200 células/m1 y en pacientes que toman más de 50 gr de alcohol al día, los coinfectados con el …
OptimizingthetreatmentofchronichepatitisduetohepatitisCvirus genotypes 2 and 3: a review
2009
A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation.
2010
Recurrent hepatitis C is a common cause of graft loss in patients undergoing liver transplantation, and serial protocol liver biopsies have been used to identify patients at risk of graft loss from rapid fibrosis progression. The aim of this study was to derive a simple noninvasive index to predict fibrosis in patients with recurrent hepatitis C post-transplant. A retrospective study was performed assessing serial liver biopsies for post-transplant chronic hepatitis C infection. One hundred eighty-five patients were included in the analysis; median age 53 years (interquartile range 48-59) and 140 (76%) were male. Liver histology showed 53 (29%) had Ishak fibrosis stages F0/F1, 31 (17%) had …
Diversity of Pharmacological Properties in Chinese and European Medicinal Plants: Cytotoxicity, Antiviral and Antitrypanosomal Screening of 82 Herbal…
2011
In an extensive screening, the antiviral, antitrypanosomal and anticancer properties of extracts from 82 plants used in traditional Chinese medicine and European phytomedicine were determined. Several promising plants that were highly effective against hepatitis B virus (HBV), bovine viral diarrhoea virus (BVDV)—a flavivirus used here as a surrogate in vitro model of hepatitis C virus, trypanosomes (Trypanosoma brucei brucei) and several cancer cell lines were identified. Six aqueous extracts from Celosia cristata, Ophioglossum vulgatum, Houttuynia cordata, Selaginella tamariscina, Alpinia galanga and Alpinia oxyphylla showed significant antiviral effects against BVDV without toxic effects …